Yesterday, Acologix Inc., a privately held biopharmaceutical company, announced that it has raised $25.3 million in Series C financing, bringing its total raised fund to over $72 million.

Most of the funds will be used to put the company's drug candidate for uremic pruritus in dialysis patients into Phase III clinical trials. Pruritus refers to an unpleasant cutaneous sensation prompting about patients to scratch, and affects approximately 70% of dialysis patients.

In addition this drug candidate, Acologix will continue the development of the following lead compounds: AC-100, a hard tissue regeneration compound, and AC-200, a drug candidate aimed at reducing serum phosphate levels associated with Chronic kidney disease.

Source: Acologix